ArticleInternational urology and nephrology2026
Analysis of acute glomerulonephritis disease burden and incidence trends in China, 1990-2021.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
purposeTo analyze and discuss the epidemiological characteristics and disease burden of acute glomerulonephritis in China from 1990 to 2021, predict its incidence in China from 2022 to 2036, and provide a reference for developing treatment and prevention strategies.
methodsData on acute glomerulonephritis in China were collected from the 2021 Global Burden of Disease database. The Joinpoint regression model was used to analyze the average annual percentage change and annual percentage change of age-standardized rates, years of life lost due to premature mortality, years lived with disability, and disability-adjusted life years. The age-period-cohort model was used to analyze the incidence from 1992 to 2021, and the Bayesian age-period-cohort method was used to predict the incidence from 2022 to 2036.
resultsStandardized incidence and mortality rates of acute glomerulonephritis in China showed a downward trend from 1990 to 2021, with average annual decreases of 4.157% and 3.861%, respectively. In 2021, the incidence and mortality rates were 7.70 (95% UI 6.55-9.01) and 0.31 (95% UI 0.21-0.40) per 100,000, respectively. The years of life lost, years lived with disability, and disability-adjusted life years also decreased. The age-period-cohort model indicated increased risk in the 0-14 and 80-99 age groups. The period effect showed a downward trend in risk from 1992 to 2021 but a slight increase since 2017. Birth cohort analysis revealed higher risks for some persons. By 2036, the male incidence may decrease to 7.38 per 100,000 while females may increase to 8.47 per 100,000.
conclusionWe observed an overall decline in disease burden and risk. However, some age groups remain at risk. We also observed a slight increase since 2012. Future projections suggest rising female incidence. Targeted interventions for high-risk groups like children, adolescents, the elderly, and females are needed to reduce the disease burden.
Indexed as
Identifiers
40828498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.